GlassScriptPhysician profile
Thurein Kyaw
NPI 1922356336
$4,180.45
in general payments reported to CMS, 2019-2025
18 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $62.18 · 2021: $149 · 2022: $597 · 2023: $710 · 2024: $965 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,587 · Food and Beverage: $1,423 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,586.66 |
| Food and Beverage | $1,422.68 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Medical Corporation | $800.00 | 2023-2025 | Defibrillator |
| Vertex Pharmaceuticals Incorporated | $786.66 | 2024-2025 | |
| Becton, Dickinson and Company | $406.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $339.38 | 2019-2025 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $284.50 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $226.46 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $223.94 | 2020-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $222.64 | 2023-2025 | Terlivaz |
| Novo Nordisk INC | $184.61 | 2025 | Wegovy, Ozempic |
| Opko Pharmaceuticals, LLC | $133.80 | 2019 | |
| Aurinia Pharma U.S., INC. | $125.01 | 2023 | Lupkynis |
| Genzyme Corporation | $112.62 | 2019 | |
| Travere Therapeutics, INC. | $111.30 | 2024 | |
| Amgen INC. | $100.86 | 2022 | |
| Vifor Pharma, INC. | $39.35 | 2022-2025 | Veltassa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $33.32 | 2024 | Xphozah 30 Mg |
| Ani Pharmaceuticals, INC. | $29.73 | 2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $20.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thurein Kyaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.